Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiolink Corp.

Division of Medtronic PLC
www.angiolink.com

Latest From Angiolink Corp.

Arthrosurface Inc.

Arthrosurface has what it believes is a robust platform technology for one of the largest, undermet opportunities in orthopedics: cartilage repair. Its HemiCAP system is a minimally invasive surgical method for treating articular lesions in the major joints with an implant that restores joints to their original geometry and function.
Medical Device

An Open Market for Vascular Access Closure Devices

After an initial warm welcome for first-generation femoral artery closure devices--including a few high-profile exits--sales have stalled. Early devices are flawed, indicating the technical challenge is tougher than it looks. A dozen or so start-ups are trying to address the technology problems that have hampered the pioneers. The newcomers face high hurdles as early experience with first generation devices temper clinician and investor enthusiasm. All will have to prove, in large, rigorous clinical trials, that devices are more complication-free and are as easy-to-use as market leader Angio-Seal, and that they're at least as safe, if not safer, than manual compression. But although start-ups face a great of skepticism about particular technologies, they also inherit a $350 million market made up of devices with an average selling price of $200, which is an endorsement of this new device market. At the same time, an enormous opportunity remains in the 75% of the market that remains unpenetrated.
Medical Device Platform Technologies

AngioLink Corp.

Ask an interventional cardiologist about the largest problems confronting his field, and most likely, closure of vascular access sites will be at the top of the list. This final step in an interventional procedure remains a weak link that adds inefficiency to procedures and discomfort to patients. Four companies with FDA-approved devices are trying to make inroads into this market, which is only 20% penetrated. AngioLink believes its device, which it claims will combine the ease-of-use of biological devices with the efficacy of mechanical closure, will encourage physician adoption.

Start-Up Previews (10/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Glycomics, features profiles of Ancora Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Optimer Pharmaceuticals Inc. and Thios Pharmaceuticals Inc. Plus these selected Start-Ups across Health Care: AngioLink Corp., PhageTech Inc., Scion Pharmaceuticals Inc. and Tensor Biosciences.
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Medtronic PLC
  • Senior Management
  • James Lousararian, CEO
    Ross Garofalo, CFO
  • Contact Info
  • Angiolink Corp.
    Phone: (508) 880-0910
    125 John Hancock Rd.
    Ste. 6
    Taunton, MA 02780
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register